Loading stock data…
Immunocore Holdings plc (IMCR)
$35.36-0.77 (-2.13%)
Market ClosedLast close Sep 8
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Immunocore Holdings plc in the Healthcare sector is trading at $35.36 with a market capitalization of $1.4B. Wall Street consensus targets $62.50 (12 analysts), implying a +76.8% move over the next 12 months. The stock is currently 13% below its 52-week high of $40.72, remaining 7.9% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +76.8% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $106.68M↑ | $104.48M↑ | $103.69M↑ | $97.96M↑ | $93.88M |
| Gross Profit | $106.24M↑ | $101.78M↓ | $103.18M↑ | $96.92M↑ | $93.05M |
| Operating Income | $7.28M↑ | -$19.69M↓ | -$7.17M↑ | -$14.88M↓ | -$3.62M |
| Net Income | $12.97M↑ | -$30.06M↓ | -$177,000↑ | -$10.30M↓ | $5.02M |
Peer Comparison
JNJUNHPFE
Fundamentals
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internatio...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.44B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.74
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-7.00%
Volume
Today's trading volume
468,739
Recent News
Immunocore's Q2 Earnings Miss Estimates, Kimmtrak Aids Y/Y Revenues
IMCR incurs wider-than-expected Q2 loss. However, revenues beat as sole drug Kimmtrak sales rise 18.3% year over year on higher U.S. and international sales.
Wall Street Analysts See a 77.91% Upside in Immunocore (IMCR): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 77.9% in Immunocore (IMCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
How Strong H1 Profits and Kimtrak Survival Data At Immunocore (IMCR) Have Changed Its Investment Story
Immunocore Holdings plc has reported past second-quarter 2026 results showing revenue of US$115.93 million, with net loss narrowing to US$0.808 million, while first-half 2026 revenue reached US$222.60 million and shifted from a prior-period loss to net income of US$12.16 million. Alongside these figures, management highlighted Kimtrak’s first-half net revenue of US$223 million and five-year survival data in metastatic uveal melanoma, underscoring the therapy’s clinical and commercial...
Immunocore Q2 Earnings Call Highlights
Immunocore (NASDAQ:IMCR) reported continued growth for KIMMTRAK in the second quarter and first half of 2026, while advancing three late-stage melanoma trials and early-stage programs in oncology, HIV and Type 1 diabetes. The company recorded $223 million in KIMMTRAK net sales during the first half
Immunocore Holdings PLC (IMCR) (Q2 2026) Earnings Call Highlights: Kimtrak Growth and Pipeline ...
Immunocore reports 16% revenue growth for Kimtrak, advances three Phase 3 trials, and maintains a robust $880 million cash position.